Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated